Provided by Tiger Fintech (Singapore) Pte. Ltd.

Guardant Health Inc.

50.03
+0.13000.26%
Post-market: 50.440.4095+0.82%19:23 EDT
Volume:2.09M
Turnover:103.65M
Market Cap:6.20B
PE:-14.81
High:50.33
Open:50.25
Low:48.07
Close:49.90
Loading ...

Guggenheim starts GH Research at Buy, sees long-term upside potential

TipRanks
·
14 Mar

GH Research Initiated at Buy by Guggenheim

Dow Jones
·
13 Mar

Guggenheim Initiates GH Research at Buy With $32 Price Target

MT Newswires Live
·
13 Mar

Sector Update: Health Care Stocks Lower in Late Afternoon Trading

MT Newswires Live
·
12 Mar

Sector Update: Health Care Stocks Slide in Afternoon Trading

MT Newswires Live
·
12 Mar

Guardant Health Shares Rise After ADLT Status for Shield Blood Test

Dow Jones
·
11 Mar

Update: Guardant Health Shares Soar After Colorectal Cancer Test Granted ADLT Status

MT Newswires Live
·
11 Mar

Guardant Health Says Colorectal Cancer Test Granted ADLT Status

MT Newswires Live
·
11 Mar

CMS approves Guardant Health ADLT status for Shield CRC screening test

TIPRANKS
·
11 Mar

Guardant Health Receives ADLT Status From CMS for Shield Blood Test

Business Wire
·
11 Mar

GH Research Initiated at Outperform by RBC Capital

Dow Jones
·
08 Mar

RBC Initiates GH Research at Outperform, Speculative Risk With $31 Price Target

MT Newswires Live
·
07 Mar

GH Research initiated with an Outperform at RBC Capital

TIPRANKS
·
07 Mar

Guardant Health Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
07 Mar

Guardant Health Base Business in 'Fundamentally Good Shape,' Morgan Stanley Says

MT Newswires Live
·
07 Mar

Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating

MT Newswires Live
·
06 Mar

Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

Business Wire
·
05 Mar

GH Research’s Promising Growth Potential: Buy Rating Backed by Strong Clinical Data and Financial Position

TIPRANKS
·
04 Mar

Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue

StockStory
·
04 Mar

Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025

Insider Monkey
·
04 Mar